Immunotherapy of cancer in the era of checkpoint inhibitor

被引：0
|
作者：
Inderjit Mehmi
Omid Hamid
机构：
[1] The Angeles Clinic and Research Institute,
[2] Cedar Sinai Affiliate,undefined
来源：
Clinical & Experimental Metastasis | 2022年 / 39卷
关键词：
Melanoma; cSCC; MCC; Immunotherapy; Checkpoint inhibitors; TIM-3; LAG-3; Cytokines; NSCLC;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Application of immunotherapy has revolutionized treatment of number of malignancies. We present a review of immunotherapy approaches, early-phase data of number of new immunotherapeutic targets in melanoma, cutaneous squamous cell carcinoma, Merkel cell cancer, and non-small cell lung cancer.
引用
收藏
页码：231 / 237
页数：6
相关论文
共 50 条
  • [21] Dermatological side effects rarely interfere with the continuation of checkpoint inhibitor immunotherapy for cancer
    Rovers, Jessica F. J.
    Bovenschen, H. Jorn
    INTERNATIONAL JOURNAL OF DERMATOLOGY, 2020, 59 (12) : 1485 - 1490
  • [22] Impact of cannabinoids on cancer outcomes in patients receiving immune checkpoint inhibitor immunotherapy
    Vigano, Marialuisa
    Wang, Lixing
    As'sadiq, Alia
    Samarani, Suzanne
    Ahmad, Ali
    Costiniuk, Cecilia T.
    FRONTIERS IN IMMUNOLOGY, 2025, 16
  • [23] Structural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumab
    Ramagopal, Udupi A.
    Liu, Weifeng
    Garrett-Thomson, Sarah C.
    Bonanno, Jeffrey B.
    Yan, Qingrong
    Srinivasan, Mohan
    Wong, Susan C.
    Bell, Alasdair
    Mankikar, Shilpa
    Rangan, Vangipuram S.
    Deshpande, Shrikant
    Korman, Alan J.
    Almo, Steven C.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2017, 114 (21) : E4223 - E4232
  • [24] Frequency of demyelinating disease activity following immune checkpoint inhibitor cancer immunotherapy
    Shemonti Hasan
    Onilia Zorio
    B. Mark Keegan
    Brian G. Weinshenker
    Eoin P. Flanagan
    W. Oliver Tobin
    Orhun H. Kantarci
    Michel Toledano
    Sean J. Pittock
    Sebastian Lopez-Chiriboga
    Anastasia Zekeridou
    Cristina Valencia-Sanchez
    Journal of Neurology, 2023, 270 : 4707 - 4712
  • [25] Inhibition of CCR2 potentiates the checkpoint inhibitor immunotherapy in pancreatic cancer
    Jung, Heiyoun
    Ertl, Linda
    Janson, Christine
    Schall, Thomas
    Charo, Israel
    CANCER IMMUNOLOGY RESEARCH, 2016, 4 (11)
  • [26] The Role of Antigen Processing and Presentation in Cancer and the Efficacy of Immune Checkpoint Inhibitor Immunotherapy
    Mpakali, Anastasia
    Stratikos, Efstratios
    CANCERS, 2021, 13 (01) : 1 - 30
  • [27] Drug resistance in cancer immunotherapy: new strategies to improve checkpoint inhibitor therapies
    Rodriguez-Pascual, Jesus
    Ayuso-Sacido, Angel
    Belda-Iniesta, Cristobal
    CANCER DRUG RESISTANCE, 2019, 2 (04) : 980 - 993
  • [28] Gut microbes modulate host response to immune checkpoint inhibitor cancer immunotherapy
    Liu, Kebin
    Lu, Chunwan
    TRANSLATIONAL CANCER RESEARCH, 2018, 7 : S608 - S610
  • [29] The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment
    Elizabeth L. Hardaker
    Emilio Sanseviero
    Ankur Karmokar
    Devon Taylor
    Marta Milo
    Chrysis Michaloglou
    Adina Hughes
    Mimi Mai
    Matthew King
    Anisha Solanki
    Lukasz Magiera
    Ricardo Miragaia
    Gozde Kar
    Nathan Standifer
    Michael Surace
    Shaan Gill
    Alison Peter
    Sara Talbot
    Sehmus Tohumeken
    Henderson Fryer
    Ali Mostafa
    Kathy Mulgrew
    Carolyn Lam
    Scott Hoffmann
    Daniel Sutton
    Larissa Carnevalli
    Fernando J. Calero-Nieto
    Gemma N. Jones
    Andrew J. Pierce
    Zena Wilson
    David Campbell
    Lynet Nyoni
    Carla P. Martins
    Tamara Baker
    Gilberto Serrano de Almeida
    Zainab Ramlaoui
    Abdel Bidar
    Benjamin Phillips
    Joseph Boland
    Sonia Iyer
    J. Carl Barrett
    Arsene-Bienvenu Loembé
    Serge Y. Fuchs
    Umamaheswar Duvvuri
    Pei-Jen Lou
    Melonie A. Nance
    Carlos Alberto Gomez Roca
    Elaine Cadogan
    Susan E. Critichlow
    Steven Fawell
    Nature Communications, 15
  • [30] Frequency of demyelinating disease activity following immune checkpoint inhibitor cancer immunotherapy
    Hasan, Shemonti
    Zorio, Onilia
    Keegan, B. Mark
    Weinshenker, Brian G. G.
    Flanagan, Eoin P. P.
    Tobin, W. Oliver
    Kantarci, Orhun H. H.
    Toledano, Michel
    Pittock, Sean J. J.
    Lopez-Chiriboga, Sebastian
    Zekeridou, Anastasia
    Valencia-Sanchez, Cristina
    JOURNAL OF NEUROLOGY, 2023, 270 (10) : 4707 - 4712
12345